For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud.
Aridis Pharmaceuticals, Inc. (ARDS) will issue 2 million shares between $13 and $15 Tuesday on the Nasdaq. Based in California, the biotech firm develops therapies for antibiotic-resistant infections, including hospital-acquired infections and cystic fibrosis. Aridis has completed Phase 2 trials for one candidate, is conducting Phase 2 studies on two others and has three more in preclinical stages.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in